WO2007083323A3 - Modified release oral dosage form comprising desmopressin - Google Patents

Modified release oral dosage form comprising desmopressin Download PDF

Info

Publication number
WO2007083323A3
WO2007083323A3 PCT/IN2007/000022 IN2007000022W WO2007083323A3 WO 2007083323 A3 WO2007083323 A3 WO 2007083323A3 IN 2007000022 W IN2007000022 W IN 2007000022W WO 2007083323 A3 WO2007083323 A3 WO 2007083323A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
desmopressin
provides
dosage
modified release
Prior art date
Application number
PCT/IN2007/000022
Other languages
French (fr)
Other versions
WO2007083323A2 (en
Inventor
Amarjit Singh
Sarabjit Singh
Shivanand Puthli
Original Assignee
Panacea Biotec Ltd
Amarjit Singh
Sarabjit Singh
Shivanand Puthli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd, Amarjit Singh, Sarabjit Singh, Shivanand Puthli filed Critical Panacea Biotec Ltd
Publication of WO2007083323A2 publication Critical patent/WO2007083323A2/en
Publication of WO2007083323A3 publication Critical patent/WO2007083323A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention describes a modified release oral dosage form of desmopressin which upon administration releases two or more amounts of desmopressin. The dosage form comprises of individual dosage units, such as an immediate release dosage unit and one or more delayed release dosage units, each comprising of a suitable amount of desmopressin, released after a predetermined time interval. The dosage form of the invention provides a release profile, adapted such that the dosage form exhibits improved efficacy for a prolonged duration of action and provides for an overall superior management of antidiuretic therapy. The invention also provides for method of manufacture of the dosage form of the invention and also method of treatment of diseases such as diabetes insipidus, nocturnal enuresis, nocturia and urinary incontinence in a mammal in need of such treatment.
PCT/IN2007/000022 2006-01-23 2007-01-19 Modified release oral dosage form comprising desmopressin WO2007083323A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN101MU2006 2006-01-23
IN101/MUM/2006 2006-01-23

Publications (2)

Publication Number Publication Date
WO2007083323A2 WO2007083323A2 (en) 2007-07-26
WO2007083323A3 true WO2007083323A3 (en) 2007-10-18

Family

ID=38288023

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2007/000022 WO2007083323A2 (en) 2006-01-23 2007-01-19 Modified release oral dosage form comprising desmopressin

Country Status (1)

Country Link
WO (1) WO2007083323A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2695634C (en) 2007-08-06 2018-01-23 Serenity Pharmaceuticals Corporation Methods and devices for desmopressin drug delivery
TW200940110A (en) * 2008-02-22 2009-10-01 Astrazeneca Ab Pharmaceutical formulation comprising oxabispidines
DK3225250T3 (en) 2008-05-21 2019-11-04 Ferring Bv Orodispersible desmopressin to prolong the initial sleep period which is not disturbed by nycturia
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
WO2012006398A2 (en) * 2010-07-09 2012-01-12 Bhv Pharma, Inc. Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
PT2704698T (en) * 2011-05-05 2019-11-19 Hennig Arzneimittel Gmbh&Co Kg Dosage form for the controlled release of active ingredients
US10278925B2 (en) 2012-01-04 2019-05-07 Wellesley Pharmaceuticals, Llc Delayed-release formulations, methods of making and use thereof
KR20180023057A (en) 2012-01-04 2018-03-06 웰즐리 파마슈티컬스 엘엘씨 Delayed-release formulation for reducing the frequency of urination and method of use thereof
RU2019101864A (en) * 2012-07-27 2019-03-11 УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи PHARMACEUTICAL COMPOSITION FOR TREATMENT OF URINE INCONTINENCE AND METHOD OF ITS USE
KR20150144209A (en) * 2014-06-16 2015-12-24 훼링 비.브이. Pharmaceutical composition comprising stabilized desmopressin or pharmaceutically acceptable salt thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000013663A1 (en) * 1998-09-09 2000-03-16 Alza Corporation Dosage form comprising liquid formulation
US20030091623A1 (en) * 1999-02-22 2003-05-15 Cumming Kenneth Iain Solid oral dosage form containing an enhancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000013663A1 (en) * 1998-09-09 2000-03-16 Alza Corporation Dosage form comprising liquid formulation
US20030091623A1 (en) * 1999-02-22 2003-05-15 Cumming Kenneth Iain Solid oral dosage form containing an enhancer

Also Published As

Publication number Publication date
WO2007083323A2 (en) 2007-07-26

Similar Documents

Publication Publication Date Title
WO2007083323A3 (en) Modified release oral dosage form comprising desmopressin
WO2009058990A3 (en) Vascular closure device
WO2006014606A3 (en) Medical devices containing copolymers with graft copolymer endblocks for drug delivery
IL201479A (en) Use of tapentadol for the manufacture of a medicament for the treatment of pain
WO2003028660A3 (en) Drug delivery devices and methods
WO2008010222A3 (en) Conjugates comprising a gaba- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating cns disorders
IL202840A (en) Substituted n-aryl pyridinones, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments for the treatment of fibrotic-mediated disorders and collagen-mediated disorders
HK1129594A1 (en) Use of substituted 2-aminotetralines for the manufacture of a medicament for the prevention, alleviation and/or treatment of various types of pain
WO2010068281A3 (en) Contact lens drug delivery device
WO2007146426A3 (en) Nanoshells for drug delivery
WO2010014690A3 (en) Medical devices for therapeutic agent delivery
WO2005070462A3 (en) Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use
WO2008087488A3 (en) Expandable medical device for the treatment and prevention of cardiovascular diseases
HK1128587A1 (en) Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
WO2007135193A3 (en) Sustained-release alcohol-resistant multimicroparticulate oral pharmaceutical form comprising anti-misuse means
WO2012091956A3 (en) Continuous indentation lateral lobe apparatus and method
WO2008028076A3 (en) Therapeutic devices for the treatment of various conditions of a female individual
WO2012018446A3 (en) Anchor delivery system
WO2007117996A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
GB0708523D0 (en) Devices, systems, and methods for medicament delivery
WO2009137827A3 (en) Controlled release of n-acetylcysteine (nac) for reduction of systemic and/or vascular inflammation
WO2005091853A3 (en) Methods and compositions for treating il-13 related pathologies
WO2008144130A3 (en) Implantable medical devices with a topcoat layer of phosphoryl choline acrylate polymer for reduced thrombosis, and improved mechanical properties
WO2007103200A3 (en) Oral controlled release formulation for sedative and hypnotic agents
WO2008141308A3 (en) Gene expression and pain

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07718257

Country of ref document: EP

Kind code of ref document: A2